Saturday 17 October 2026
Export WST’s income statement to Excel — free account
West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
382.92
0.10
−0.03%
Follow WST
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
40.28 | 48.53 | 43.70 | 29.79 | 52.58 | 60.41 | 45.97 | 35.01 | 48.54 | 42.89 |
Piotroski F-Score |
8 | 4 | 5 | 6 | 7 | 7 | 5 | 8 | 6 | 8 |
P/S ratio |
6.47 | 8.26 | 8.78 | 6.04 | 12.32 | 9.75 | 6.05 | 4.22 | 4.60 | 4.08 |
Altman Z-Score |
13.89 | 18.08 | 19.59 | 14.36 | 24.46 | 15.92 | 11.19 | 10.06 | 9.95 | 8.63 |
Altman Z″-Score (non-manufacturers) |
9.34 | 9.30 | 9.54 | 9.62 | 8.72 | 7.25 | 7.17 | 7.59 | 6.82 | 6.29 |
P/FCF ratio |
42.77 | 87.72 | 63.08 | 40.04 | 106.78 | 71.14 | 46.37 | 39.89 | 56.48 | 131.39 |
Beneish M-Score |
(2.79) | (2.51) | (2.74) | (2.52) | (2.18) | (2.60) | (2.49) | (2.57) | (2.56) | (2.55) |
P/Operating CF |
79.22 | 125.79 | 108.35 | 75.56 | 217.00 | 140.80 | 104.55 | 98.97 | 90.22 | 85.83 |
Dividend Safety Score |
100 | — | — | — | — | — | — | — | — | — |
P/B ratio |
6.26 | 8.91 | 8.99 | 6.50 | 14.94 | 11.29 | 7.07 | 5.19 | 5.75 | 5.51 |
Price to Tangible BV |
6.50 | 9.32 | 9.40 | 6.81 | 15.84 | 12.22 | 7.75 | 5.70 | 6.39 | 6.22 |
EV/Sales |
6.28 | 8.17 | 8.52 | 5.80 | 12.13 | 9.58 | 5.95 | 4.14 | 4.57 | 4.10 |
EV/EBITDA |
25.52 | 32.58 | 30.89 | 19.60 | 39.26 | 39.87 | 27.35 | 20.61 | 22.68 | 21.64 |
EV/Operating CF |
25.58 | 36.16 | 32.36 | 23.14 | 58.80 | 43.54 | 29.79 | 24.61 | 27.78 | 28.19 |
EV/FCF |
41.51 | 86.68 | 61.18 | 38.46 | 105.08 | 69.91 | 45.60 | 39.11 | 56.18 | 131.89 |
Quick Ratio |
2.09 | 1.88 | 2.03 | 2.70 | 2.11 | 1.99 | 2.22 | 2.21 | 1.75 | 1.67 |
Current Ratio |
3.02 | 2.79 | 2.88 | 3.70 | 2.93 | 2.73 | 3.10 | 3.15 | 2.66 | 2.66 |
Net Debt/EBITDA |
(0.78) | (0.39) | (0.96) | (0.80) | (0.63) | (0.70) | (0.46) | (0.41) | (0.12) | 0.08 |
Debt/Assets |
4.75% | 5.56% | 1.90% | 5.71% | 6.30% | 9.05% | 10.89% | 9.90% | 10.58% | 13.18% |
Debt/Equity |
0.06 | 0.08 | 0.03 | 0.08 | 0.09 | 0.14 | 0.16 | 0.14 | 0.15 | 0.20 |
Asset Turnover |
0.78 | 0.77 | 0.79 | 0.83 | 0.93 | 0.84 | 0.85 | 0.89 | 0.89 | 0.88 |
Operating CF/Net income |
1.53 | 1.33 | 1.31 | 1.24 | 0.88 | 1.36 | 1.52 | 1.39 | 1.75 | 1.53 |
Capex/Depreciation |
(1.67) | (2.43) | (2.64) | (2.36) | (2.07) | (1.60) | (1.22) | (1.00) | (1.35) | (1.88) |
Interest Coverage |
1,169.80 | 189.97 | 75.11 | 92.91 | 91.74 | 49.62 | 34.89 | 28.61 | 28.95 | 24.10 |
| 16.85% | 17.71% | 21.32% | 23.34% | 31.59% | 20.20% | 16.28% | 15.46% | 12.57% | 13.41% | |
| 12.48% | 13.19% | 15.94% | 16.91% | 21.67% | 13.48% | 11.19% | 10.77% | 8.42% | 8.42% | |
ROIC |
14.13% | 14.84% | 20.12% | 22.97% | 26.39% | 17.05% | 13.34% | 11.97% | 11.37% | 10.70% |
Return on Tangible Assets |
16.19% | 19.18% | 22.16% | 22.90% | 30.01% | 19.09% | 15.53% | 14.44% | 11.43% | 12.18% |
Average Days of Receivables |
68.20 | 69.70 | 63.35 | 64.15 | 63.03 | 65.51 | 63.34 | 61.25 | 57.79 | 48.49 |
Research and Development Expense of Revenue |
2.42% | 2.39% | 2.32% | 2.03% | 1.86% | 2.18% | 2.11% | 2.35% | 2.45% | 2.44% |
Selling, General and Administrative Expense of Revenue |
12.80% | 11.70% | 11.98% | 10.98% | 12.81% | 14.07% | 14.82% | 15.31% | 15.38% | 15.88% |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 |
Share Based Compensation of Revenue |
0.77% | 0.65% | 0.79% | 0.82% | 1.32% | 1.58% | 1.33% | 0.88% | 1.01% | 1.29% |
Graham Net Nets |
0.04 | 0.02 | 0.04 | 0.06 | 0.02 | 0.02 | 0.03 | 0.04 | 0.02 | 0.01 |
Graham Number |
82.16 | 74.70 | 83.44 | 79.94 | 79.37 | 51.46 | 39.55 | 34.50 | 28.26 | 25.93 |
Earnings Yield |
2.48% | 2.06% | 2.29% | 3.36% | 1.90% | 1.66% | 2.18% | 2.86% | 2.06% | 2.33% |
Free Cash Flow Yield |
2.34% | 1.14% | 1.59% | 2.50% | 0.94% | 1.41% | 2.16% | 2.51% | 1.77% | 0.76% |
Revenue per Share |
42.52 | 39.63 | 39.70 | 38.80 | 38.06 | 29.05 | 24.86 | 23.24 | 21.64 | 20.59 |
Operating CF per Share |
10.44 | 8.95 | 10.45 | 9.73 | 7.85 | 6.39 | 4.96 | 3.91 | 3.56 | 2.99 |
Capex per Share |
(3.95) | (5.16) | (4.87) | (3.83) | (3.41) | (2.36) | (1.71) | (1.42) | (1.77) | (2.32) |
Free Cash Flow per Share |
6.49 | 3.79 | 5.58 | 5.91 | 4.44 | 4.03 | 3.25 | 2.49 | 1.79 | 0.67 |
Cash per Share |
10.94 | 6.64 | 11.49 | 12.02 | 10.25 | 8.33 | 5.93 | 4.57 | 3.19 | 2.77 |
Shareholders Equity per Share |
43.93 | 36.74 | 38.78 | 36.09 | 31.39 | 25.09 | 21.26 | 18.89 | 17.32 | 15.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
43.93 | 36.74 | 38.78 | 36.09 | 31.39 | 25.09 | 21.26 | 18.89 | 17.32 | 15.25 |
Free Cash Flow |
468.90 | 276.40 | 414.50 | 439.40 | 330.60 | 298.10 | 240.80 | 183.90 | 132.50 | 49.20 |
Working Capital |
1,323.30 | 987.70 | 1,264.60 | 1,400.50 | 1,147.90 | 870.30 | 717.10 | 610.70 | 464.00 | 400.90 |
Capital Expenditures |
(285.90) | (377.00) | (362.00) | (284.60) | (253.40) | (174.40) | (126.40) | (104.70) | (130.80) | (170.20) |
Net Current Asset Value |
884.20 | 577.00 | 987.90 | 987.60 | 763.60 | 434.40 | 290.50 | 311.80 | 160.60 | 42.70 |
EV/EBIT |
33.00 | 41.46 | 37.17 | 22.82 | 45.65 | 50.56 | 36.89 | 29.56 | 32.39 | 31.69 |
Capex to Sales |
0.09 | 0.13 | 0.12 | 0.10 | 0.09 | 0.08 | 0.07 | 0.06 | 0.08 | 0.11 |
Price to Operating Income |
34.01 | 41.96 | 38.33 | 23.76 | 46.38 | 51.45 | 37.51 | 30.15 | 32.56 | 31.57 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.10 | 0.10 | 0.10 | 0.12 | 0.12 | 0.12 | 0.13 | 0.11 | 0.12 |
Cash ROIC |
11.24% | 8.20% | 10.89% | 11.61% | 10.00% | 10.95% | 10.62% | 9.53% | 7.74% | 3.18% |
Accounts Receivable Turnover |
5.46 | 5.44 | 5.79 | 5.79 | 6.48 | 6.09 | 6.06 | 6.34 | 7.05 | 7.90 |
Accounts Payable Turnover |
7.99 | 7.87 | 7.95 | 7.82 | 7.44 | 7.46 | 8.59 | 8.73 | 8.35 | 8.34 |
Inventory Turnover |
4.80 | 4.67 | 4.29 | 4.41 | 4.73 | 4.95 | 5.48 | 5.46 | 5.24 | 5.30 |
Average Days of Payables |
47.00 | 46.10 | 48.60 | 44.91 | 51.19 | 56.40 | 46.37 | 40.61 | 46.41 | 44.19 |
Days of Inventory on Hand |
82.24 | 72.63 | 87.15 | 86.48 | 83.41 | 85.04 | 69.71 | 66.80 | 72.31 | 72.19 |
Average Receivables |
563.45 | 532.25 | 509.70 | 498.20 | 437.15 | 352.30 | 303.75 | 270.70 | 226.85 | 190.95 |
Average Payables |
246.50 | 240.85 | 228.90 | 223.80 | 222.65 | 184.95 | 143.60 | 134.25 | 130.05 | 120.90 |
Average Inventory |
410.45 | 405.85 | 424.75 | 396.60 | 349.85 | 278.50 | 225.10 | 214.85 | 207.25 | 190.20 |
Average Assets |
3,956.70 | 3,736.45 | 3,723.15 | 3,465.30 | 3,053.80 | 2,567.60 | 2,160.15 | 1,920.85 | 1,789.75 | 1,705.90 |
Average Common Equity |
2,929.15 | 2,781.65 | 2,782.95 | 2,510.15 | 2,094.95 | 1,713.85 | 1,484.75 | 1,338.10 | 1,198.70 | 1,070.70 |
Columns are period end dates